Our fifth Convergence will focus on the specific challenges facing personalized medicine integration.
Diaceutics’ Convergence meetings are ’unique integration events’ bringing together expert stakeholders from across the personalized medicine space. This year's Convergence focus – our fifth to date - will remain firmly on personalized medicine (PM) integration but with a deeper dive into the specific challenges facing integration of testing and treatment today, inclusive of education, policy and technology barriers. We intend as well to showcase examples of best practise being deployed to address some of these barriers and feature an update to the launch of the PM CONNECTIVE, a not for profit organization focused on test and treatment integration in key diseases, which was conceived during the 2014 Convergence summit.
Thought leaders, new to the usual PM circuit, will provide the meeting with fresh eyes on the increasingly competitive and fast moving PM world. Dr Tamer Shahin, CEO of Nuviun, will challenge our thinking on big data. Tamer is well positioned to provide a glimpse of the future as he leads a bold new on the ground initiative to build connected health systems for the United Arab Emirates. Jeffrey Waldron, Executive Director, PM Connective, will outline the far reaching steps the PM Connective is planning to take to teach the industry how to better integrate personalized medicine. Karen Heichman, Vice President of Oncology Technology Development & Licensing, ARUP Laboratories, will discuss the role of the laboratory in implementing personalized medicine.
In addition, the agenda will be peppered with fresh insights from the Diaceutics team on such topics as which competitive events which will shape 2016 and how pharma is succeeding and failing at branding and communicating personalized medicine.
You can view the latest agenda using the following link: http://www.diaceutics.com/CM/agenda.html